Skip to main content
PMC home page
Journal of Clinical Laboratory Analysis logoLink to Journal of Clinical Laboratory Analysis
. 2007 May 16;21(3):173–177. doi: 10.1002/jcla.20163

Association between vitamin‐D receptor gene FokI polymorphism and Graves' disease among Taiwanese Chinese

Rong‐Hsing Chen 1, Chwen‐Tzuei Chang 1, Huey‐Yi Chen 2,3, Wen‐Chi Chen 2,4, Chang‐Hai Tsai 5,6, Fuu‐Jen Tsai 2,5,✉
PMCID: PMC6649158  PMID: 17506475

Abstract

1,25(OH)2D3, exerting its biological effects through the vitamin‐D receptor (VDR), plays a role in the modulation of the human immune system. The aim of this study was to test for the presence of an association between VDR gene polymorphism and the susceptibility to Graves' disease (GD) for Taiwanese Chinese. Using a polymerase chain reaction (PCR)‐based restriction analysis, we screened the VDR exon 2 start codon T/C (VDR‐FokI) polymorphism to determine the genotypes for 88 GD patients and 90 normal controls. From the genotype analysis, GD patients featured a greater proportion of the CC genotype (44.3%) and a smaller proportion of the TT genotype (12.5%) than was the case for normal controls (CC: 23.3% and TT: 28.9%; chi‐squared test, P=0.003). The odds ratios (ORs) for the risk of the CC genotype's appearance compared with the corresponding values for the TT and TC genotypes, for the GD patient group, were, 4.39 (95% confidence interval [CI]: 1.82–10.61) and 2.10 (95% CI: 1.06–4.18), respectively. With respect to the allelic analysis, we observed significantly increased C‐allele (65.9%) and decreased T‐allele (34.1%) frequencies among GD patients compared to normal controls (C: 47.2% and T: 52.8%; chi‐squared test, P=0.002). The OR for the risk of appearance of the C allele in the GD‐patient group was 1.93 (95% CI: 1.27–2.95). In conclusion, the VDR‐FokI T/C polymorphism might be able to be used as a genetic marker to predict the likelihood of GD development. J. Clin. Lab. Anal. 21:173–177, 2007. © 2007 Wiley‐Liss, Inc.

Keywords: Graves' disease, vitamin‐D receptor, FokI, polymorphism

REFERENCES

  • 1. Larsen PR, Alexander NM, Chopra IJ, et al. Revised nomenclature for tests of thyroid hormones and thyroid‐related proteins in serum. J Clin Endocrinol Metab 1987;64:1089–1092. [DOI] [PubMed] [Google Scholar]
  • 2. Di Paola R, Menzaghi C, De Filippis V, Corda D, Di Cerbo A. Cyclooxygenase‐dependent thyroid cell proliferation induced by immunoglobulins from patients with Graves' disease. J Clin Endocrinol Metab 1997;82:670–673. [DOI] [PubMed] [Google Scholar]
  • 3. Kriss JP, Pleshakov V, Chien JR. Isolation and identification of the long‐acting thyroid stimulator and its relation to hyperthyroidism and circumscribed pretibial myxedema. J Clin Endocrinol 1964;24:1005–1028. [DOI] [PubMed] [Google Scholar]
  • 4. Romagnani S. Th1 and Th2 in human diseases. Short analytic review. Clin Immunol Immunopathol 1996;80:225–235. [DOI] [PubMed] [Google Scholar]
  • 5. Kocjan T, Wraber B, Repnik U, Hojker S. Changes in Th1/Th2 cytokine balance in Graves' disease. Eur J Physiol 2000;400(Suppl):94–95. [PubMed] [Google Scholar]
  • 6. Mosmann TR. Cytokine secretion patterns and cross‐regulation of TH1 and TH2 responses. Immunol Today 1991;12:A49–A53. [DOI] [PubMed] [Google Scholar]
  • 7. Walters MR. Newly identified actions of the vitamin D endocrine system. Endocr Rev 1992;13:719–764. [DOI] [PubMed] [Google Scholar]
  • 8. Muller K, Bendtzen K. Inhibition of human T lymphocyte proliferation and cytokine production by 1,25‐dihydroxyvitamin D3. Differential effects on CD45RA+ and CD45R0+cells. Autoimmunity 1992;14:37–43. [DOI] [PubMed] [Google Scholar]
  • 9. Lemire JM. Immunomodulatory actions of 1,25‐dihydroxyvitamin D3. J Steroids Biochem Mol Biol 1995;53:599–602. [DOI] [PubMed] [Google Scholar]
  • 10. Lemire JM, Archer DC, Beck L, Spiegelberg HL. Immunosuppressive actions of 1,25‐dihydroxyvitamin D3: preferential inhibition of Th1 functions. J Nutr 1995;125(Supp):1704S–1708S. [DOI] [PubMed] [Google Scholar]
  • 11. Fournier C, Gepner P, Sadouk M, Charreire J. In vivo beneficial effects of cyclosporine A and 1,25‐dihydroxyvitamin D3 on induction of experimental autoimmune thyroiditis. Clin Immunol Immunopathol 1990;54:53–63. [DOI] [PubMed] [Google Scholar]
  • 12. Kawakami‐Tani T, Fukawa E, Tanaka H, Abe Y, Makino I. Effect of a alpha‐hydroxyvitamin D3 on serum levels of thyroid hormones in hyperthyroidism patients with untreated Graves' disease. Metabolism 1997;46:1184–1188. [DOI] [PubMed] [Google Scholar]
  • 13. Ban Y, Taniyama M, Ban Y. Vitamin D receptor gene polymorphism is associated with Graves' disease in the Japanese population. J Clin Endocrinol Metab 2000;85:4639–4643. [DOI] [PubMed] [Google Scholar]
  • 14. Ban Y, Ban Y, Taniyama M, Katagiri T. Vitamin D receptor initiation codon polymorphism in Japanese patients with Graves' disease. Thyroid 2000;10:475–480. [DOI] [PubMed] [Google Scholar]
  • 15. Ramos‐Lopez E, Kurylowicz A, Bednarczuk T, Paunkovic J, Seidl C, Badenhoop K. Vitamin D receptor polymorphisms are associated with Graves' disease in German and Polish but not in Serbian patients. Thyroid 2005;15:1125–1130. [DOI] [PubMed] [Google Scholar]
  • 16. Collins JE, Heward JM, Nithiyananthan R, Nejentsev S, Todd JA, Fraklyn JA, Gough SC. Lack of association of the vitamin D receptor gene with Graves' disease in UK Caucasians. Clin Endocrinol 2004;60:618–624. [DOI] [PubMed] [Google Scholar]
  • 17. Harris S, Eccleshall TR, Gross C, Dawson‐Hughes B, Feldman D. The vitamin D receptor start codon polymorphism (FokI) and bone mineral density in premenopausal American Black and White women. J Bone Miner Res 1997;12:1043–1048. [DOI] [PubMed] [Google Scholar]
  • 18. Chen QY, Huang W, She JX, Baxter F, Volpe R, Maclaren MK. HLA‐DRB1*08, DRB1*03/DRB3*0101, and DRB3*0202 are susceptibility genes for Graves' disease in North American Caucasians, whereas DRB1*07 is protective. J Clin Endocrinol Metab 1999;84:3182–3186. [DOI] [PubMed] [Google Scholar]
  • 19. Yanagawa T, Taniyama M, Enomoto S, et al. CTLA4 gene polymorphism confers susceptibility to Graves' disease in Japanese. Thyroid 1997;7:843–846. [DOI] [PubMed] [Google Scholar]
  • 20. Tomer Y, Davies TF. Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. Endocr Rev 2003;24:694–717. [DOI] [PubMed] [Google Scholar]
  • 21. Mangelsdolf DJ, Evans RM. The RXR heterodimers and orphan receptor. Cell 1995;83:841–850. [DOI] [PubMed] [Google Scholar]
  • 22. Gross C, Eccleshall TR, Mallory PJ, Villa ML, Marcus R, Feldman D. The prevalence of a polymorphism at the translation initiation site of the vitamin D receptor gene is associated with low bone mineral density in postmenopausal Mexican‐American women. J Bone Miner Res 1996;11:1850–1855. [DOI] [PubMed] [Google Scholar]
  • 23. Arai H, Miyamoto K, Taketani Y, et al. A vitamin D receptor gene polymorphism in the translation initiation codon: effect on protein activity and relation to bone mineral density in Japanese women. J Bone Miner Res 1997;12:915–921. [DOI] [PubMed] [Google Scholar]
  • 24. Jurutka PW, Remus LS, Whitefield GK, et al. The polymorphic N terminus in human vitamin D receptor isoform influences transcriptional activity by modulation interaction with transcription factor IIB. Mol Endocrinol 2000;14:401–420. [DOI] [PubMed] [Google Scholar]
  • 25. Cardon LR, Palmer LJ. Population stratification and spurious allelic association. Lancet 2003;361:598–604. [DOI] [PubMed] [Google Scholar]
  • 26. Colhoun HM, McKeigue PM, Davey Smith G. Problems of reporting genetic association with complex outcomes. Lancet 2003;361:865–872. [DOI] [PubMed] [Google Scholar]
  • 27. Sterne JA, Davey Smith G. Shift the evidence—what's wrong with significance tests? BMJ 2001;322:226–231. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Clinical Laboratory Analysis are provided here courtesy of Wiley

RESOURCES